Basilea Press News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Basilea press. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Basilea Press Today - Breaking & Trending Today

Basilea Pharmaceutica AG: Basierend auf positiven Phase-3-Ergebnissen bereitet Basileas Partner Asahi Kasei Pharma die Einreichung eines Antrags auf Marktzulassung (NDA) von Isavuconazol in Japan vor

Basilea Pharmaceutica AG: Basierend auf positiven Phase-3-Ergebnissen bereitet Basileas Partner Asahi Kasei Pharma die Einreichung eines Antrags auf Marktzulassung (NDA) von Isavuconazol in Japan vor
Basel, 26. Juli 2021
Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) beabsichtigt, auf Basis der positiven Ergebnisse der kürzlich abgeschlossenen Phase-3-Studie, in der Patienten mit tiefsitzenden Mykosen behandelt worden waren, für das Antimykotikum Isavuconazol (Cresemba
) einen Antrag auf Marktzulassung (New Drug Application, NDA) in Japan zu stellen. Asahi Kasei Pharma plant, Topline-Ergebnisse der Studie zu einem späteren Zeitpunkt zu veröffentlichen. ....

United States , July Basilea , Sher Corporation , Services Or Achievements Of Basilea , S Partnership , Basilea Press , Swiss Exchange , Request For , Market Approval , Hoc Notification , Japanese Patient , John Primary Endpoint , Treatment Side Effects , Fungal Infections , Years Running , For Approval , Isavuconazole Patient , New Sales Markets , Tee Payment , Percent Range , Product Sales , End March , Prior Year Period , About Isavuconazole , Member States , Active Ingredient Orphan Drug Status ,

GNW: Basierend auf positiven Phase-3-Ergebnissen bereitet Basileas Partner | Newsticker

Ad hoc-Mitteilung gemäss Art. 53 KR
Basel, 26. Juli 2021
Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) beabsichtigt, auf Basis der positiven Ergebnisse der kürzlich abgeschlossenen Phase-3-Studie, in der Patienten mit tiefsitzenden Mykosen behandelt worden waren, für das Antimykotikum Isavuconazol (Cresemba(R)) einen Antrag auf Marktzulassung (New Drug Application, NDA) in Japan zu stellen. Asahi Kasei Pharma plant, Topline-Ergebnisse der Studie zu einem späteren Zeitpunkt zu veröffentlichen.
Die multizentrische, Open-label-Phase-3-Studie untersuchte bei insgesamt 103 Patienten die Sicherheit und Wirksamkeit von intravenös und oral gegebenem Isavuconazol bei erwachsenen japanischen Patienten mit tiefsitzenden Mykosen, einschliesslich invasiver Aspergillose, chronischer pulmonaler Aspergillose (Chronic Pulmonary Aspergillosis, CPA), Mukormykose und Kryptokokkose.1 Primärer Endpunkt der ....

United States , July Basilea , Sher Corporation , Services Or Achievements Of Basilea , S Partnership , Basilea Press , Swiss Exchange , Request For , Market Approval , Hoc Notification , Japanese Patient , John Primary Endpoint , Treatment Side Effects , Fungal Infections , Years Running , For Approval , Isavuconazole Patient , New Sales Markets , Tee Payment , Percent Range , Product Sales , End March , Prior Year Period , Above Isavuconazole , Member States , Active Ingredient Orphan Drug Status ,

Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding

Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding
Basel, Switzerland, February 23, 2021
Basilea Pharmaceutica Ltd ( Basilea or the Company ) announced today the launch of an offering of up to 1 million new registered shares with a par value of CHF 1.00 per share. The net proceeds from this private placement will be used for i) the clinical development of Basilea s clinical oncology drug candidates derazantinib and lisavanbulin, ii) pre-clinical research and development activities, and iii) working capital and other general corporate purposes, including investments in or in-licensing of complementary businesses, products or assets.
The new shares correspond to approximately 8% of Basilea s currently issued share capital and will be issued from the Company s authorized share capital, excluding subscription rights of existing shareholders. The offer price of the new shares will be determined in an accelera ....

Basel Stadt , United States , United Kingdom , Nils Schr , Bryan Garnier , Head Of Corporate Communications Investor Relations , Credit Suisse , Financial Services , Swiss Exchange , Basilea Pharmaceutica Ltd , United Kingdom European Union Withdrawal , Swiss Financial Services , Cantor Fitzgerald , European Union , Basilea Press , Swiss Exchange On , Pharmaceutica Ltd , Securities Act , Joint Bookrunners , United Kingdom European Union , European Economic Area , United Kingdom Prospectus Regulation , Markets Act , Financial Promotion , Qualified Investors , Qualified Investor ,